March Biosciences is testing its MB-105 cell therapy in a Phase 2 clinical trial for people with difficult-to-treat cancer. Photo via march.bio

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

This year's award recipients span industries and technologies. Photos courtesy

2024 Houston Innovation Awards winners named at annual event

drum roll, please...

Houston innovators — the moment you've been waiting for. The winners of the 2024 Houston Innovation Awards were named at the annual event.

The Houston Innovation Awards honored over 40 finalists across categories, naming the 12 winners and honoring the two Trailblazer Legacy Awards at the event.

The 2024 judges — who represent various industries and verticals in Houston — scored over 200 submissions. The event, hosted at TMC Helix Park on November 14 and emceed by Joey Sanchez, 2023 Ecosystem Builder award recipient and founder of Cup of Joey, revealed the winners.

The event's sponsors included Texas Medical Center, Milam & Greene, EIGHT Beer, Houston Community College, Microsoft, Halliburton Labs, Mercury, Pillsbury Winthrop Shaw Pittman LLP, Rice Innovation & Ion District, Growth Pods, Hunton Andrews Kurth and more.

Without further adieu, here the winners from the 2024 Houston Innovation Awards.

Corrolytics is a technology startup founded to solve microbiologically influenced corrosion problems for industrial assets. Co-founder and CEO Anwar Sadek says he's collected over $1 million in dilutive and non-dilutive funding from grants and other opportunities thanks to help from mentors.

"As a founder, I am always eager to assist and support fellow entrepreneurs, especially those navigating the unique challenges that come with being a BIPOC founder," he says. "With the guidance of mentors, I learned to master the complexities of the application process for grants and other funding opportunities. In turn, I actively share my experiences with other founders, helping them navigate similar paths."

Koda Health is a provider of a tech-enabled care coordination service for improving serious illness care planning. Founder and CEO Tatiana Fofanova says that her company's last fundraise has been one of her biggest career challenges to date.

"In a venture downturn that only cared about artificial intelligence, I closed my second round six days before I gave birth to my son," she says. "Fundraising in enterprise health tech is a tough task on a good year. Fundraising in an AI-obsessed downturn while seven months pregnant was the greatest physical and professional challenge of my life. I was only able to do such a Herculean feat through the support of my husband, my amazing professional network, and the Koda team."

March Biosciences, a clinical-stage cell therapy company with a mission to transform patient care in the most challenging hematological malignancies, was co-founded by CEO Sarah Hein.

"Our therapy has resulted in multiple long-term remissions in patients with advanced T cell lymphoma, which is unheard," Hein says on what sets March apart. "Our drug is simpler, cheaper, and more efficient to produce than any of our competition's approaches. And our company operates with a lean, fit-for-purpose structure that allows us to move faster and more efficiently than industry norms."

Founded by CEO Cindy Taff, Sage Geosystems is an energy company focused on developing and deploying advanced geothermal technologies to provide reliable power and sustainable energy storage solutions regardless of geography.

"Sage Geosystems sets itself apart from competitors with its Geopressured Geothermal Systems, which can be deployed almost anywhere, unlike traditional geothermal technologies that require specific geographic conditions," Taff says. "This flexibility enables Sage to provide a reliable and virtually limitless power supply, making it ideal for energy-intensive applications like data centers."

Venus Aerospace, a deep tech company founded by husband and wife team Sassie and Andrew Duggleby, is developing reusable hypersonic technology for aviation, defense, and beyond. The team says its company culture is what drives its success.

"Traditionally, the aerospace industry tends to burn out its employees with no room for work- life balance. One of our core visions is being 'home for dinner,'" the company reported. "We want to fly you to one side of the world and still have you home for dinner. And if you work for Venus, we expect you to not only get your job done, but prioritize your family and make it home in time for dinner."

Cognitive Space, an automated satellite operations provider that enables constellations to scale, was founded by CEO Guy de Carufel, who worked at NASA for eight years before starting this company.

Cognitive Space, working in defense sector, provides "AI for automating the space infrastructure, from effective ordering across multiple data providers, to optimized scheduling of satellite operations from sensor and link management," de Carufel says. "Addressing complexities in managing heterogeneous space systems at scale."

Cart.com is a unified commerce and logistics solutions provider for B2C and B2B companies is a fast-growing ecommerce platform founded by CEO Omair Tariq.

"In the last 12 months, Cart.com has dramatically grown its fulfillment network’s scale and technological capabilities," writes CEO Omail Tariq in his Houston Innovation Awards application. "We have been laser-focused on improving quality, performance and efficiency at scale while continuing to aggressively grow our customer base, expand our capabilities to customers in new industries and grow our physical presence to new locations. Prioritizing our strategic growth initiatives has been critical in the current macroeconomic environment as profitable growth remains paramount for our team."

Corrolytics, a technology startup founded to solve microbiologically influenced corrosion problems for industrial assets, secured the most votes from the Houston innovation community.

"If I could give myself advice before starting the company, I would say to embrace the challenges early on, as they are invaluable learning opportunities," Co-founder and CEO Anwar Sadek says. "Focus on building a strong network, especially with mentors and industry leaders who can guide you through the unknowns. Lastly, be prepared for the unexpected, stay adaptable, and never underestimate the importance of a clear mission that inspires both your team and your customers."

Impact Hub Houston is a nonprofit that serves as a pivotal hub within the city's innovation ecosystem, fostering a dynamic environment where changemakers, entrepreneurs, and community leaders converge to drive social impact and innovation forward.

"We mobilize problem solvers to use their knowledge, skills and technology to address community challenges, demonstrating our commitment to local impact while also providing a global reach for Houston innovators," says Grace Rodriguez, founder and CEO of the organization. "Our work extends to supporting underrepresented communities, and we work with public and private stakeholders to promote sustainable business practices that prioritize economic development, environmental stewardship and social equity."

Mitra Miller is the vice president of Houston Angel Network, but also founded and chairs Eagle Investors, a nonprofit group teaching students about the investment and innovation community. She serves as an active mentor for many organizations across Houston.

"Houston has the most friendly, open, collaborative, and inclusive innovation environment anywhere," Miller says. "When I ask individuals and organizations to partner on events and initiatives, they readily agree and give freely of their time and resources. There is a generosity of spirit that is very special to Houston."

Juliana Garaizar, founding partner of Energy Tech Nexus, invests with groups — such as Portfolia, Houston Angel Network, Business Angel Minority Association, and more — locally and beyond.

"I'm a hands on investor," she says. "I offer mentorship and industry and other investor connections. I take advisory roles and board observer seats."

Phillip Yates is the founder and CEO of Equiliberty Inc., but wears a few other hats too. In 2011, he helped establish a pre-venture business incubator at the Houston Area Urban League Entrepreneurship Center. He served as general counsel for the Business Angel Minority Association and Direct Digital Holdings Inc., and currently serves as chairman of Impact Hub Houston.

"My favorite part of Houston's innovative ecosystem is the growing network of resources for founders," he says. "Given our racial, ethnic and culturally diverse population, we have a wider range of experiences and perspectives — and ideas that lead to better problem solving, creative solutions and understanding of the needs our community."

This year, the Houston innovation community suffered the loss of two business leaders who left a significant impact on the ecosystem. Both individuals' careers were recognized with Trailblazer Legacy Awards.

Paul Frison, founder of the Houston Technology Center, and Scott Gale, executive director of Halliburton Labs, received the award posthumously. Frison died on September 5, and Gale died on September 24. The award was decided on by the 2024 judges and InnovationMap.

“I am immensely proud to honor these two remarkable individuals with the Trailblazer Award this year. It is fitting, as they represent two generations of building Houston’s ecosystem," 2023 Trailblazer Award recipient Brad Burke, managing director of the Rice Alliance and the associate vice president for industry and new ventures within Rice University's Office of Innovation, tells InnovationMap.

"Paul Frison was a pioneering leader who helped establish the Houston Technology Center and fostered the city’s tech ecosystem during the initial technology boom around the year 2000. Scott Gale, through his work at Halliburton Labs over the past five years, has been instrumental in launching Houston’s energy transition ecosystem," he continues. "Both have played pivotal roles in championing technology innovators.” Continue reading.

This week's roundup of Houston innovators includes Bryton Praslicka of FluxWorks, Sarah Hein of March Biosciences, Jerin Varkey of Offer Approved. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes three founders across therapeutics, space, and sports tech.

Bryton Praslicka, CEO and founder of FluxWorks

FluxWorks, a hardtech startup, opened its new home-base in Conroe, Texas. Photo courtesy FluxWorks

FluxWorks, a hardtech startup, recently opened its new base of operations in Workhub Developments’ Conroe location.

Founded in College Station by CEO Bryton Praslicka, FluxWorks specializes in making contactless magnetic gears for use in extreme conditions. At 9,000 square feet, the new Conroe facility is a result of discussions with Governor Greg Abbott's office and the Greater Houston Partnership, who introduced the company’s leadership to the Conroe Economic Development Council, encouraging their move, Praslicka tells InnovationMap.

“The pieces of the puzzle were all there, and with the support of the local, state, and federal government, we were thrilled to move to Conroe,” Paslicka says. Read more.

Sarah Hein, co-founder and CEO of March Biosciences

Sarah Hein joins the Houston Innovators Podcast to discuss how the company will use its series A funding. Photo via march.bio

When cancer originates in a patient, their body fights as hard as it can against the disease, but sometimes, the cancer wins the battle. However, one Houston cell therapy startup is working on an artillery of therapeutics to help arm patients' bodies to win the war.

Founded in 2022, March Biosciences is a cell therapy company born in part out of the Texas Medical Center's Accelerator for Cancer Therapeutics, where Sarah Hein served as inaugural entrepreneur in residence. In that role, she met her co-founders Max Mamonkin and Malcolm Brenner.

Now, leading the startup as CEO, Hein tells the Houston Innovators Podcast that with March's lead product, MB-105, an autologous CD5 CAR T cell therapy, the name of the game is to zero in on advancing this particular treatment to its phase II trial next year.

"Targeted therapies are targeted. Our target is expressed on these T-cell cancers, and there are a couple other cancers, like Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia," Hein says on the show. "Unfortunately, I don't think there's ever going to be a magic bullet that is going to hit a huge swath of these cancers. We're going to continue to chip away at these cancers by creating really elegantly engineered therapies against these different kinds of tumors.

"March, in general, is committed to this idea that we're going to continue to work on difficult tumors and different targets with our uniquely engineered targeting strategy against these diseases. As we expand into the next year, you'll see us speak on this a little more on how we're going to continue to work on new diseases that havent been addressed previously," she continues. Read more.

Jerin Varkey, founder and CEO of Offer Approved

Looking to score the best deal on your next game ticket? A new Houston-founded app promises to revolutionize the resale market. Photo via LinkedIn

Online platforms have long simplified the process of buying, selling, and trading event tickets. But what happens when your tickets don’t sell or when you’re stuck with costly season tickets you can’t use? You might end up giving them away or leaving them unused, leading to a financial loss either way.

This is the challenge that Houstonian Jerin Varkey is willing to address with Offer Approved, a new platform that empowers sellers and buyers, guaranteeing that no seat goes unused.

The idea took root around two years ago when Varkey, a passionate sports fan and season ticket holder, faced a new challenge. After becoming a parent, he found himself unable to attend every game. Frustrated with traditional resale platforms, he quickly realized that high fees and limited time made it difficult to sell all his tickets, causing him to lose money each time.

"I knew there was someone out there willing to pay $50," he recalls. Read more.

Sarah Hein, co-founder and CEO of March Biosciences, joins the Houston Innovators Podcast to discuss how the company will use its series A funding. Photo via march.bio

With fresh funding, Houston cancer-fighting cell therapy gears up for continued clinical trials

Houston innovators podcast episode 259

When cancer originates in a patient, their body fights as hard as it can against the disease, but sometimes, the cancer wins the battle. However, one Houston cell therapy startup is working on an artillery of therapeutics to help arm patients' bodies to win the war.

Founded in 2022, March Biosciences is a cell therapy company born in part out of the Texas Medical Center's Accelerator for Cancer Therapeutics, where Sarah Hein served as inaugural entrepreneur in residence. In that role, she met her co-founders Max Mamonkin and Malcolm Brenner.

Now, leading the startup as CEO, Hein tells the Houston Innovators Podcast that with March's lead product, MB-105, an autologous CD5 CAR T cell therapy, the name of the game is to zero in on advancing this particular treatment to its phase II trial next year.

"Targeted therapies are targeted. Our target is expressed on these T-cell cancers, and there are a couple other cancers, like Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia," Hein says on the show. "Unfortunately, I don't think there's ever going to be a magic bullet that is going to hit a huge swath of these cancers. We're going to continue to chip away at these cancers by creating really elegantly engineered therapies against these different kinds of tumors.

"March, in general, is committed to this idea that we're going to continue to work on difficult tumors and different targets with our uniquely engineered targeting strategy against these diseases. As we expand into the next year, you'll see us speak on this a little more on how we're going to continue to work on new diseases that havent been addressed previously," she continues.

Hein explains how March Biosciences — named in part as a nod to one of Houston's best months weather wise — has benefitted from the support of the local life science community. Last year, March announced its partnership with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience. Hein says over the past year, they've moved into CTMC and that's allowed them to accelerate their progress as a company.

"Houston has a unique sophistication in cell therapy. Where we've had biotech spinout, cell therapy has been one of our more successful verticals," she says. "We've had resources and knowledge here that were uniquely available for our drug category."

Earlier this month, March Biosciences announced an oversubscribed $28.4 million series A led by Mission BioCapital and 4BIO Capital and bringing the company's total funding secured to more than $51 million, including its prestigious CPRIT grant. Hein says this funding will go toward further developing March's therapeutics and team as it gears up for its phase II trial next year.

Ultimately, Hein explains on the show how passionate she is and her team is on continuing to develop treatments to fight cancer with their targeted approach.

"I never have to explain to people why we would go out and fight cancer. I think it's a self-evident hypothesis," she says. "But what I personally find is exciting in cancer therapies in general are these immune therapies, where you using the body's own immune system to seek out and destroy the cancer cells.

"What's really exciting about that is these are the same immune cells that fight cancer or pre-cancers for most of your life and usually what happens is the cancers figure out a way to mass themselves. With modern approaches, we can boost the immune system."

This week's roundup of Houston innovators includes Sarah Hein of March Biosciences, Sean Kelly of Amperon, Donnell Debnam Jr. of the Google in Residence program, and the 2023 Houston Innovation Awards judges. Photos courtesy

3+ Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries, from biotech to energy software, recently making headlines in Houston innovation — plus the decision makers for the Houston Innovation Awards.

Sarah Hein, CEO and co-founder of March Biosciences

Early-stage cell therapy startup March Biosciences has partnered with CTMC. Photo via march.bio

Named in part after one of the best months out of the year for Houstonians, March Biosciences has entered into a uniquely Houston partnership. Sarah Hein, CEO and co-founder of the cancer immunotherapy startup, met her co-founders at the TMC Accelerator for Cancer Therapeutics.

“It's a perfect example of the opportunities here in Houston where you can go from bench to bedside, essentially, in the same institution. And Baylor has been particularly good at that because of the Center for Cell and Gene Therapy,” says Hein.

The company recently announced a partnership with another Houston institution, CTMC. Read more.

Sean Kelly, CEO and co-founder of Amperon

It's payday for a startup that's improving analytics for its energy customers. Photo via Getty Images

Amperon Holdings Inc. raised $20 million in its latest round of funding in order to accelerate its energy analytics and grid decarbonization technology.

The fresh funding will support the company in evolving its platform that conducts electricity demand forecasting to a comprehensive data analytics solution.

“The energy transition is creating unprecedented market volatility, and Amperon is uniquely positioned to help market participants better navigate the transitioning grid – both in the U.S. and as we expand globally,” Sean Kelly, CEO and co-founder of Amperon, says. Read more.

Donnell Debnam Jr., instructor in the Google in Residence program

Thanks to Google, Donnell Debnam Jr. is helping train future software engineers at Prairie View A&M University. Photo via LinkedIn

Computer science students at Prairie View A&M University are gaining firsthand knowledge this semester from a Google software engineer.

As an instructor in the Google in Residence program, Donnell Debnam Jr. is helping train future software engineers — and other potential tech professionals — who are enrolled this fall in Prairie View A&M’s introductory computer science course. Fifty-four students are taking the class.

“I participated in the Google in Residence program as a student, and I am honored to return as an instructor,” says Debnam. “This innovative program was created to support greater diversity in the tech industry, and as an instructor, I have the privilege of helping the next generation of software engineers create a more inclusive culture within the STEM fields.” Read more.

2023 Houston Innovation Awards judges

Bonus innovators to know: The 10 Houstonians deciding the finalists and winners for this year's Houston Innovation Awards. Photos courtesy

Ten Houstonians are in the hot seat for deciding the best companies and individuals in Houston's innovation ecosystem.

InnovationMap has announced its 2023 Houston Innovation Awards judging panel, which includes startup founders, nonprofit leaders, investors, corporate innovators, and more.

Meet the 10 selected judges who will evaluate applications from the nearly 400 nominations that were submitted this year. Read more.

Early-stage cell therapy startup March Biosciences has partnered with CTMC. Photo via march.bio

Cancer-fighting startup partners with Houston cell therapy accelerator

marching on

When it came time to name their cell therapy startup, Houston life science innovators simply had to look to their calendar.

“I would argue that March is the best month in Houston,” Sarah Hein tells InnovationMap. “We started talking about putting this company together during COVID, so we were outside a lot. And we actually got together in March.”

That’s why the CEO and her co-founders Max Mamonkin and Malcolm Brenner decided to name their company March Biosciences.

It's a fresh, unstuffy name for a startup that has an innovative take on cancer immunotherapy. Their lead asset is an advanced cellular therapy known as MB-105, an autologous CD5 CAR T cell therapy. For patients with T-cell lymphoma and leukemia who have failed all currently available lines of therapy, the prognosis is understandably extremely poor. But in a phase one study, MB-105 has been proven to safely treat those patients. The phase two study is expected to begin in the first half of 2024.

Hein met Mamonkin at the TMC Accelerator for Cancer Therapeutics (ACT), at which the alumna of Resonant Therapeutics and Courier Therapeutics was an entrepreneur in residence.

“It's a perfect example of the opportunities here in Houston where you can go from bench to bedside, essentially, in the same institution. And Baylor has been particularly good at that because of the Center for Cell and Gene Therapy,” says Hein.

The serial entrepreneur first came to Houston as a PhD student in molecular and cellular biology at Baylor College of Medicine, but during her studies she became excited by the startup ecosystem in her new hometown. After earning her degree, she became a venture fellow at the Mercury Fund. Her experience in both science and business made her an ideal candidate to take March Biosciences to the next level.

In September, the company announced that it formed a strategic alliance with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience.

“Our unique risk-sharing model allows us to collaborate with organizations like March Biosciences to accelerate the development and manufacture of innovative cell therapies, like MB-105, and bring them into the clinic with a consistent and scalable manufacturing process,” said CTMC’s CEO, Jason Bock in a press release.

The partnership “has allowed us to move really quickly,” Hein says.

That’s because what CTMC does uniquely well is take early stage companies like March Biosciences and advance them to a state that’s ready for manufacturing in a short time, around 18 months, says Hein.

According to Hein, March Biosciences’ success is a testament to Houston and its world-class medical center.

“It’s a great example of the opportunities you see here in Houston, where we have a technology that was developed by brilliant scientists here in Houston and we can pull together the resources that we need to take it to the next level,” Hein says. "Working with partners here in Houston, we have all the pieces and the community rises to the occasion to support you.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Houston to add new AI lab for energy startups

AI partnership

Greentown Labs has partnered with Shoreless to launch an AI lab within its Houston climatetech incubator.

"Climatetech and energy startups are transforming industries, and AI is a critical tool in that journey," Lawson Gow, Greentown's Head of Houston, said in a news release. "We're excited to bring this new offering to our entrepreneurs and corporate partners to enhance the way they think about reducing costs and emissions across the value chain."

Shoreless, a Houston-based company that enables AI adoption for enterprise systems, will support startups developing solutions for supply-chain optimization and decarbonization. They will offer Greentown members climate sprint sessions that will deliver AI-driven insights to assist companies in reducing Scope 3 emissions, driving new revenue streams and lowering expenses. Additionally, the lab will help companies test their ideas before attempting to scale them globally.

"The future of climatetech is intertwined with the future of AI," Ken Myers, Founder and CEO of Shoreless, said in a news release. "By launching this AI lab with Greentown Labs, we are creating a collaborative ecosystem where innovation can flourish. Our agentic AI is designed to help companies make a real difference, and we are excited to see the groundbreaking solutions that will emerge from this partnership."

Greentown and Shoreless will collaborate on workshops that address industry needs for technical teams, and Shoreless will also work to provide engagement opportunities and tailored workshops for Greentown’s startups and residents. Interested companies can inquire here.

Recently, Greentown Labs also partnered with Los Angeles-based software development firm Nominal to launch the new Industrial Center of Excellence at Greentown's Houston incubator. It also announced a partnership with Houston-based EnergyTech Nexus, which will also open an investor lounge on-site last month. Read more here.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston medical institutions launch $6M kidney research incubator

NIH funding

Institutions within Houston’s Texas Medical Center have launched the Houston Area Incubator for Kidney, Urologic and Hematologic Research Training (HAI-KUH) program. The incubator will be backed by $6.25 million over five years from the National Institutes of Health and aims to create a training pipeline for researchers.

HAI-KUH will include 58 investigators from Baylor College of Medicine, Texas Children’s Hospital, the University of Texas Health Science Center at Houston, University of Houston, Houston Methodist Research Institute, MD Anderson Cancer Center, Rice University and Texas A&M University Institute of Biosciences and Technology. The program will fund six predoctoral students and six postdoctoral associates. Trainees will receive support in scientific research, professional development and networking.

According to the organizations, Houston has a high burden of kidney diseases, hypertension, sickle cell disease and other nonmalignant hematologic conditions. HAI-KUH will work to improve the health of patients by building a strong scientific workforce that leverages the team's biomedical research resources to develop research skills of students and trainees and prepare them for sustained and impactful careers. The funding comes through the National Institute of Diabetes and Digestive and Kidney Diseases.

The principal investigators of the project include Dr. Alison Bertuch, professor of pediatric oncology and molecular and human genetics at BCM; Peter Doris, professor and director of the Institute of Molecular Medicine Center for Human Genetics at UT Health; and Margaret Goodell, professor and chair of the Department of Molecular and Cellular Biology at Baylor.

“This new award provides unique collaborative training experiences that extend beyond the outstanding kidney, urology, and hematology research going on in the Texas Medical Center,” Doris said in a news release. “In conceiving this award, the National Institute of Diabetes and Digestive and Kidney Diseases envisioned trainee development across the full spectrum of skills required for professional success.”

Jeffrey Rimer, a professor of Chemical Engineering, is a core investigator on the project and program director at UH. Rimer is known for his breakthroughs in using innovative methods in control crystals to help treat malaria and kidney stones. Other co-investigators include Dr. Wolfgang Winkelmeyer (Baylor), Oleh Pochynyuk (UTHealth), Dr. Rose Khavari (Houston Methodist) and Pamela Wenzel (UT Health).

“This new NIH-sponsored training program will enable us to recruit talented students and postdocs to work on these challenging areas of research,” Rimer added in a release.

6 Houston health tech startups making major advancements right now

meet the finalists

Home to leading hospitals, universities and health-focused incubators, Houston is a breeding ground for innovative medical technology and breakthroughs that can improve outcomes and lead to a better quality of life for patients.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Six forward-thinking businesses have been named finalists for the 2025 award. They range from an end-of-life care company to others developing devices and systems for heart monitoring, sleep apnea, hearing loss and more.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below. Then join us at the Houston Innovation Awards on Nov. 13 at Greentown Labs, when the winner will be unveiled at our live awards ceremony.

Tickets are now on sale for this exclusive event celebrating all things Houston Innovation.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient. The system is currently in the research and development phase and is being used in clinical trials and studies.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. It raised a pre-seed round last year of $435,000.

Corveus Medical

Corveus Medical has developed a novel catheter device that allows cardiologists to perform a splanchnic nerve ablation, restoring the pressure balance in patients with moderate heart failure. Its pre-FDA-approved, minimally invasive solution deactivates a nerve that has been demonstrated to be a root cause behind heart failure progression, which allows physicians to treat patients who have traditionally had few options.

The company, formerly known as Caridian Medical, was founded in 2021 by CEO Tyler Melton and CMO Ishan Kamat. It has participated in incubators such as TMC Biodesign, Y Combinator, MedTech Innovator and Fogarty Innovation and was named one of the 10 most promising life science companies at Texas Life Science Forum in 2022. The company says it will move toward validation and verification testing for its device in Q4 of this year.

FibroBiologics

Regenerative medicine company FibroBioligics uses fibroblasts, the body’s most common type of cell, rather than stem cells, to help grow new cells to repair tissue and modulate the immune system. The cell therapies offer treatments for chronic conditions such as degenerative disc disease, multiple sclerosis and non-healing wounds.

The publicly traded company was founded in 2021 by CEO Pete O'Heeron. It opened a new 10,000-square-foot Houston lab earlier this year to scale up research efforts and pave the way for in-house manufacturing. The company says it plans to launch its first clinical trial for diabetic foot ulcers soon, representing the transition of its fibroblast technology to the clinic setting.

Koda Health

Koda Health has developed an advance care planning platform (ACP) that allows users to document and share their care preferences, goals and advance directives for health systems. The web-based platform guides patients through values-based decisions with interactive tools and generates state-specific, legally compliant documents that integrate seamlessly with electronic health record systems. The company also added kidney action planning to its suite of services for patients with serious illnesses last year.

Koda Health was founded out of the TMC's Biodesign Fellowship in 2020 by CEO Tatiana Fofanova, chief medical officer Dr. Desh Mohan, and chief technology officer Katelin Cherry. The company raised a $7 million series A earlier this year, and also announced major partnerships and integrations with Epic, Guidehealth, Medical Home Network, Privia Health and others.

NanoEar

NanoEar has miniaturized hearing aid technology so that it can be implanted across the eardrum, allowing adults with age-related hearing loss to enjoy better sound quality than they would with behind-the-ear hearing aids.

Dr. Ron Moses, an ENT specialist and surgeon at Houston Methodist, developed the technology, and the company was founded in 2016 with CFO Willem Vermaat and COO Michael Moore. The company participated in the TMC Innovation Institute in 2016. It has issued nine U.S. patents and performed successful human cadaver and animal proof-of-concept experiments. Its next step is developing a prototype.

Wellysis USA

Wellysis USA Inc. works to detect heart rhythm disorders with its continuous ECG/EKG monitor with AI reporting. Its S-Patch cardiac monitor is designed for extended testing periods of up to 14 days on a single battery charge. The device weighs only 9 grams, is waterproof and designed to be comfortable to wear, and is considered to have a high detection rate for arrhythmias. It is ideally suited for patient-centric clinical trials to help physicians make diagnoses faster, cheaper and more conveniently.

It was established in Houston in 2023 and participated in the JLABS SFF Program the same year. It closed a $12 million series B last year. It was founded by CEO Young Juhn, CTO Rick Kim, CFO JungSoo Kim and chief strategy officer JoongWoo Kim.

---

The Houston Innovation Awards program is sponsored by Houston Community College, Houston Powder Coaters, FLIGHT by Yuengling, and more to be announced soon. For sponsorship opportunities, please contact sales@innovationmap.com.